Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression

Experimental and Molecular Pathology

Volumn 81, Issue 2, 2006, Pages 146-156

  Sharma, Meena R ^b   Koltowski, Lauren ^a   Ownbey, Robert T ^a   Tuszynski, George P ^c   Sharma, Mahesh C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Angiostatin; Annexin II; Breast cancer; Invasion; Plasmin

Indexed keywords

ANGIOSTATIN; LIPOCORTIN 2; MONOCLONAL ANTIBODY; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; INVASIVE CARCINOMA; NORTHERN BLOTTING; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANGIOSTATINS; ANNEXIN A2; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELL MEMBRANE; CELL MOVEMENT; CELLS, CULTURED; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PLASMINOGEN;

EID: 33750812269     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.03.003     Document Type: Article

References (44)

1. Aguilar S., Corominas J.M., Malats N., Pereira J.A., Dufresne M., Real F.X., and Navarro P. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am. J. Pathol. 165 (2004) 1129-1139
2. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., and Foidart J.M. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152 (2001) 777-784
3. Bell W.R. The fibrinolytic system in neoplasia. Semin. Thromb. Hemost. 22 (1996) 459-478
4. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., and Hanash S.M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9824-9829
5. Brownstein C., Deora A.B., Jacovina A.T., Weintraub R., Gertler M., Khan K.M., Falcone D.J., and Hajjar K.A. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 103 (2004) 317-324
6. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., and Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17 (1997) 439-444
7. Cesarman G.M., Guevara C.A., and Hajjar K.A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA): II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269 (1994) 21198-21203
8. Chappuis P.O., Dieterich B., Sciretta V., Lohse C., Bonnefoi H., Remadi S., and Sappino A.P. Functional evaluation of plasmin formation in primary breast cancer. J. Clin. Oncol. 19 (2001) 2731-2738
9. Chiang Y., Rizzino A., Sibenaller Z.A., Wold M.S., and Vishwanath J.K. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol. Cell. Biochem. 199 (1999) 139-147 (In process citation)
10. Collen D., and Lijnen H.R. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb. Haemost. 74 (1995) 167-171
11. Costantini V., Zacharski L.R., Memoli V.A., Kudryk B.J., Rousseau S.M., and Stump D.C. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res. 51 (1991) 354-358
12. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., and Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44 (1985) 139-266
13. DeClerck Y.A., Imren S., Montgomery A.M., Mueller B.M., Reisfeld R.A., and Laug W.E. Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425 (1997) 89-97
14. Devy L., deGroot F.M., Blacher S., Hajitou A., Beusker P.H., Scheeren H.W., Foidart J.M., and Noel A. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. FASEB J. 18 (2004) 565-567
15. Diaz V.M., Hurtado M., Thomson T.M., Reventos J., and Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53 (2004) 993-1000
16. Felez J., Miles L.A., Fabregas P., Jardi M., Plow E.F., and Lijnen R.H. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb. Haemost. 76 (1996) 577-584
17. Gershtein ES., and Kushlinskii N.E. The clinical prospects for the study of the plasminogen activation system in breast cancer. Vestn. Ross. Akad. Med. (1999) 58-61
18. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., and Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6367-6372
19. Hajjar K.A., Jacovina A.T., and Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator: I. Identity with annexin II. J. Biol. Chem. 269 (1994) 21191-21197
20. Janicke F., Schmitt M., Ulm K., Gossner W., and Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2 (1989) 1049
21. Ling Q., Jacovina A.T., Deora A., Febbraio M., Simantov R., Silverstein R.L., Hempstead B., Mark W.H., and Hajjar K.A. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest. 113 (2004) 38-48
22. Liotta L.A., Rao C.N., and Barsky S.H. Tumor invasion and the extracellular matrix. Lab. Invest. 49 (1983) 636-649
23. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Ferno M., Eppenberger-Castori S., Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brunner N., Duggan C., Lisboa B.W., Bendahl P.O., Quillien V., Daver A., Ricolleau G., Meijer-vanGelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broet P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V., Klijn J.G., O'Higgins N., Eppenberger U., Janicke F., Schmitt M., and Foekens J.A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94 (2002) 116-128
24. McColl B.K., Baldwin M.E., Roufail S., Freeman C., Moritz R.L., Simpson R.J., Alitalo K., Stacker S.A., and Achen M.G. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 198 (2003) 863-868
25. Mignatti P., and Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73 (1993) 161-195
26. Mulligan-Kehoe M.J., Wagner R., Wieland C., and Powell R. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. J. Biol. Chem. 276 (2001) 8588-8596
27. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689-692
28. Ossowski L., and Aguirre-Ghiso J.A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12 (2000) 613-620
29. Peyruchaud O., Serre C.M., NicAmhlaoibh R., Fournier P., and Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J. Biol. Chem. 278 (2003) 45826-45832
30. Rabbani S.A., and Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 62 (2002) 2390-2397
31. Roseman B.J., Bollen A., Hsu J., Lamborn K., and Israel M.A. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol. Res. 6 (1994) 561-567
32. Sharma M.C., and Shapiro B.H. Purification and characterization of constituent testosterone 2 alpha-hydroxylase (cytochrome P450(2)alpha) from mouse liver. Arch. Biochem. Biophys. 316 (1995) 478-484
33. Sharma M.C., Agrawal A.K., Sharma M.R., and Shapiro B.H. Interactions of gender, growth hormone, and phenobarbital induction on murine Cyp2b expression. Biochem. Pharmacol. 56 (1998) 1251-1258
34. Sharma M.R., Tuszynski G.P., and Sharma M.C. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J. Cell. Biochem. 91 (2004) 398-409
35. Sharma, M., Rothman, V.L., Tuszynski, G.P.A., Sharma M.C., in press. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. Exp. Mol. Pathol. 81, 136-145.
36. Stephens R.W., Brunner N., Janicke F., and Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res. Treat. 52 (1998) 99-111
37. Tarui T., Majumdar M., Miles L.A., Ruf W., and Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J. Biol. Chem. 277 (2002) 33564-33570
38. Terranova V.P., Hujanen E.S., and Martin G.R. Basement membrane and the invasive activity of metastatic tumor cells. J. Natl. Cancer Inst. 77 (1986) 311-316
39. Tuszynski G.P., Sharma M., Rothman V.L., and Sharma M.C. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc. Res. 64 (2002) 448-462
40. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., and Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84 (1992) 1875-1887
41. Westphal J.R., Van't Hullenaar R., Geurts-Moespot A., Sweep F.C., Verheijen J.H., Bussemakers M.M., Askaa J., Clemmensen I., Eggermont A.A., Ruiter D.J., and De Waal R.M. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int. J. Cancer 86 (2000) 760-767
42. Wu W., Tang X., Hu W., Lotan R., Hong W.K., and Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin. Exp. Metastasis 19 (2002) 319-326
43. Xing R.H., and Rabbani S.A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer 67 (1996) 423-429
44. Zimmermann U., Woenckhaus C., Pietschmann S., Junker H., Maile S., Schultz K., Protzel C., and Giebel J. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch. 445 (2004) 368-374